Verve Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Verve Therapeutics es Sek Kathiresan , nombrado en Jul 2019, tiene una permanencia de 5.33 años. compensación anual total es $9.32M, compuesta por 6.4% salario y 93.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.8% de las acciones de la empresa, por valor de $3.26M. La antigüedad media del equipo directivo y de la junta directiva es de 3 años y 3.5 años, respectivamente.
Información clave
Sek Kathiresan
Chief Executive Officer (CEO)
US$9.3m
Compensación total
| Porcentaje del salario del CEO | 6.4% |
| Permanencia del CEO | 5.3yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 3.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$197m |
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$197m |
| Dec 31 2023 | US$9m | US$597k | -US$200m |
| Sep 30 2023 | n/a | n/a | -US$193m |
| Jun 30 2023 | n/a | n/a | -US$192m |
| Mar 31 2023 | n/a | n/a | -US$179m |
| Dec 31 2022 | US$8m | US$571k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$148m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$137m |
| Dec 31 2021 | US$6m | US$519k | -US$120m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$99m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$2m | US$480k | -US$46m |
Compensación vs. Mercado: La compensación total de Sek($USD9.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.14M).
Compensación vs. Ingresos: La compensación de Sek ha aumentado mientras la empresa no es rentable.
CEO
Sek Kathiresan (52 yo)
5.3yrs
Permanencia
US$9,319,782
Compensación
Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Director at Relay Therapeutics, Inc. since July 2022. He is a Founder at Maze Therapeutics, Inc and Director from September 2022. He is Co-Foun...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 5.3yrs | US$9.32m | 0.80% $ 3.3m | |
| CFO & Principal Accounting Officer | 3yrs | US$3.48m | 0.0048% $ 19.7k | |
| President | 6.3yrs | US$3.32m | 0.40% $ 1.7m | |
| Co-Founder | no data | sin datos | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| Co-Founder & Scientific Advisory Board Member | no data | US$7.97k | sin datos | |
| Co-Founder | no data | sin datos | sin datos | |
| Co-Founder & Strategic Advisor | no data | sin datos | sin datos | |
| Chief Scientific Officer | less than a year | sin datos | 0.0021% $ 8.7k | |
| Chief Administrative Officer | 1.8yrs | sin datos | 0.010% $ 42.0k | |
| Vice President of Investor Relations & Corporate Communications | 3yrs | sin datos | sin datos | |
| Executive Director of Human Resources | 1.8yrs | sin datos | sin datos |
3.0yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de VERV se considera experimentado (3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 5.3yrs | US$9.32m | 0.80% $ 3.3m | |
| Co-Founder & Scientific Advisory Board Member | 3.2yrs | US$7.97k | sin datos | |
| Co-Founder & Independent Chairman of the Board | 6.8yrs | US$451.88k | 0.51% $ 2.1m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 3.5yrs | US$521.07k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$412.38k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$407.38k | 0% $ 0 | |
| Director | less than a year | sin datos | sin datos | |
| Independent Director | 6.3yrs | US$410.88k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$405.88k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos |
3.5yrs
Permanencia media
54.5yo
Promedio de edad
Junta con experiencia: La junta directiva de VERV se considera experimentada (3.5 años de antigüedad promedio).